News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

|Articles|March 6, 2018

Thrombectomy for Stroke: 5 Important Facts

Author(s)Andrew N. Wilner, MD

Dr. Wilner discusses 5 key points from a recent study on thrombectomy 6 to 16 hours after stroke.

In this narrated slide show, neurologist Andrew Wilner reviews and summarizes 5 key points of the DEFUSE-3 study, entitled "Thrombectomy for Stroke at 6-16 Hours With Selection by Perfusion Imaging," published in February 2018 in The New England Journal of Medicine. ¹

Reference

1. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Eng J Med. 2018;378:708-718.

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Content

World Brain Day: Emerging Ways to Prevent Neurologic Conditions

ByMarco Meglio,Isabella Ciccone, MPH

July 22nd 2026

FDA Action Update, June 2026: Acceptances, Clearances, and Alignments

ByIsabella Ciccone, MPH

July 6th 2026

FDA Clears PoNS Device for Stroke Rehabilitation, Expanding Neurostimulation Beyond MS Indication

July 3rd 2026

Extending the Treatment Window for Thrombolysis in Acute Ischemic Stroke: Fan Z. Caprio, MD

ByFan Z. Caprio, MD,Isabella Ciccone, MPH

June 11th 2026

FDA Action Update, May 2026: Approvals, Priority Review, and Extension of Review

ByIsabella Ciccone, MPH

June 10th 2026

Latest CME

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

James F. Howard Jr, MD, FAAN

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Katherine Ruzhansky, MD, MS

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA, FASCO; Girish Dhall, MD

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Abigail Schwaede, MD; Alexis Lizarraga, MD, MS

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline

Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial

Sanofi's Oral TREM2 Agonist SAR448851 Advances to Phase 2 TREMHANCE Trial in Early Alzheimer Disease

Highlighting Gaps in Testing and Diagnosis for Fragile X Syndrome: Craig A. Erickson, MD

The Hidden Cost of the Beautiful Game: Part 1